Scopus
YÖKSİS Eşleşti
Long term outcomes of prostate cancer patients aged 55 years or younger treated with definitive radiotherapy: Trod 09-005 study
Strahlentherapie Und Onkologie · Ocak 2025
YÖKSİS Kayıtları
Long term outcomes of prostate cancer patients aged 55 years or younger treated with definitive radiotherapy: Trod 09-005 study
Strahlentherapie und Onkologie · 2025 SCI-Expanded
DOÇENT HAMİT BAŞARAN →
Makale Bilgileri
DergiStrahlentherapie Und Onkologie
Yayın TarihiOcak 2025
Scopus ID2-s2.0-105017023262
Özet
Purpose: Evidence on the use of definitive radiotherapy (RT) in younger prostate cancer (PCa) patients is limited, with no national-level studies systematically evaluating oncologic outcomes and treatment-related toxicity in this population. This study aimed to assess oncologic outcomes and toxicity of definitive prostate RT in patients aged 55 years or younger. Methods: Records of 180 PCa patients aged ≤ 55 years treated with definitive RT ± androgen deprivation therapy across 12 cancer centers were retrospectively reviewed. Primary endpoints included freedom from biochemical failure (FFBF) and PCa-specific survival (PCSS). Secondary endpoints were overall survival (OS), acute/late genitourinary (GU) and gastrointestinal (GI) toxicities, local recurrence (LR), and distant metastasis (DM). Results: Median age was 54 years; median PSA at diagnosis was 10.4 ng/mL. Risk group distribution was 29% low-, 29% intermediate-, and 42% high-risk. Median RT dose was 76 Gy delivered in 38 fractions. After a median follow-up of 106.2 months, local recurrence (9%), distant metastasis (7%), and isolated PSA progression (3%) were noted. The 8‑year FFBF, PCSS, and OS were 85.7%, 93.8%, and 90.3%, respectively. Univariate analysis identified PSA, clinical T stage, Gleason score (GS), and risk group as significant prognostic factors for FFBF and PCSS. Multivariate analysis showed advanced stage and high GS independently predicted worse FFBF and PCSS. Acute and late grade ≥ 2 GU toxicity occurred in 12% and 6%, and GI toxicity in 11% and 3%. Conclusion: Definitive radiotherapy is a safe and effective treatment for prostate cancer patients aged ≤ 55 years. Prospective studies are needed to confirm these findings.
Yazarlar (17)
1
Caglayan Selenge Beduk Esen
2
Aysenur Elmali
3
Birhan Demirhan
4
Ozan Cem Guler
5
Selvi Tabak Dincer
6
Ilknur Alsan Cetin
7
Meral Kurt
8
Mustafa Akin
9
Ertugrul Senturk
10
Serap Akyurek
ORCID: 0000-0001-8840-0233
11
Halil Cumhur Yildirim
12
Gulhan Guler Avci
13
Pelin Altinok
14
Hamit Basaran
15
Gokhan Ozyigit
16
Pervin Hurmuz
17
Cem Onal
ORCID: 0000-0002-2742-9021
Anahtar Kelimeler
Prostate cancer
Radiotherapy
Survival
Toxicity
Young age
Kurumlar
Ankara Üniversitesi
Ankara Turkey
Balıkesir Atatürk City Hospital
Balikesir Turkey
Başkent Üniversitesi
Ankara Turkey
Bursa Uludağ Üniversitesi
Bursa Turkey
Gazi University, Faculty of Medicine
Ankara Turkey
Hacettepe Üniversitesi
Ankara Turkey
Iskenderun Gelisim Hospital
Hatay Turkey
Istanbul University-Cerrahpasa
Istanbul Turkey
Marmara Üniversitesi Tip Fakültesi
Istanbul Turkey
Prof. Dr. Cemil Tascioglu City Hospital
Istanbul Turkey
Selçuk Tip Fakültesi
Konya Turkey
Tokat Gaziosmanpaşa Üniversitesi
Tokat Turkey
Umraniye Training and Research Hospital
Istanbul Turkey